华润双鹤：子公司产品通过仿制药一致性评价

Core Viewpoint - China Resources Double Crane Pharmaceutical (华润双鹤) announced that its wholly-owned subsidiary Anhui Double Crane Pharmaceutical Co., Ltd. and its holding subsidiary Double Crane Tianan Pharmaceutical (Guizhou) Co., Ltd. received approval from the National Medical Products Administration for the supplementary applications of two drugs: Dextrose Sodium Chloride Injection and Metformin Empagliflozin Tablets (I) [1] Group 1 - Dextrose Sodium Chloride Injection has passed the consistency evaluation of quality and efficacy for generic drugs, primarily used for cerebrovascular diseases. The total R&D investment for this drug as of the announcement date is 2.7253 million yuan, with an estimated domestic market sales of 658 million yuan in 2024 [1] - Metformin Empagliflozin Tablets (I) has received approval for a change in the marketing authorization holder, with the drug approval number remaining unchanged. The total R&D investment for this drug as of the announcement date is 5.1956 million yuan, with an estimated domestic market sales of approximately 340 million yuan in 2024 [1]